- Streamline operations at Mizushima Works and realign derivative-product supply chains by fiscal 2030; company says there is no immediate impact on supply.
- Exit low-margin derivative businesses (¥116.2bn revenue in FY2025 vs. ¥1,306.2bn for the Material segment) to improve margins and reduce cash outflows.
- Actions follow cessation of ethylene production at AMEC and include collaboration with Mitsui Chemicals and Mitsubishi Chemical on ethylene decarbonization.
Restructuring plan
Asahi Kasei will streamline operations at its Mizushima Works and realign derivative-product supply chains by fiscal 2030; the company says there will be no immediate impact on supply of derivative products.
Financial scope
The businesses covered recorded ¥116.2 billion revenue in fiscal 2025 against ¥1,306.2 billion for the Material segment overall; the move targets exit from low‑margin derivative businesses to improve margins and reduce cash outflows.
Strategic context
The measures follow the previously announced cessation of ethylene production at Asahi Kasei Mitsubishi Chemical Ethylene Corp. (AMEC) and form part of the three‑year medium‑term management plan “Trailblaze Together,” which aims to enhance capital efficiency and reallocate resources to pharmaceuticals, critical care, overseas homes and electronics.
Recent related actions
Recent steps cited include a basic agreement with Mitsui Chemicals and Mitsubishi Chemical to promote decarbonization of ethylene production in western Japan and the acquisition of Aicuris to bolster the company’s specialty pharmaceutical capabilities in severe infectious diseases.
